Impact of Dapagliflozin on DIAstolic Dysfunction in Type 2 Diabetic Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02751398|
Recruitment Status : Completed
First Posted : April 26, 2016
Last Update Posted : August 11, 2020
This study aims to assess the impact of 24-week treatment of dapagliflozin in type 2 DM(diabetes mellitus) patients on diastolic dysfunction. Primary endpoint is assessing the impact of 24-week treatment of dapagliflozin in type 2 DM patients on subclinical diastolic dysfunction assessed by supine bicycle diastolic stress echocardiography. Secondary endpoint is assessing the impact of 24-week treatment of dapagliflozin in type 2 DM patients on functional capacity, he impact of 24-week treatment of dapagliflozin in type 2 DM patients at resting diastolic function. This is single-center, randomized, double-blind, placebo-controlled, parallel-arm intervention study.
This study is planned to evaluate the impact of dapagliflozin on diastolic dysfunction assessed. The dose of dapagliflozin will be 10 mg as approved.
For assessment of diastolic dysfunction, supine bicycle stress exercise echocardiography was performed, and changes in diastolic functional reserve, VO2max, exercise time, and maximal exercise capacity were assessed before and after treatment. This study will be randomized, double blind, placebo controlled, to minimize the risk of bias.
|Condition or disease||Intervention/treatment||Phase|
|Type 2 Diabetes Mellitus||Drug: Dapagliflozin 10mg Drug: Placebo 10mg||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Impact of Dapagliflozin on DIAstolic Dysfunction in Type 2 Diabetic Patients: The IDDIA Study|
|Actual Study Start Date :||August 18, 2016|
|Actual Primary Completion Date :||June 15, 2020|
|Actual Study Completion Date :||June 15, 2020|
Drug: Dapagliflozin 10mg
|Placebo Comparator: Placebo||
Drug: Placebo 10mg
Matching placebo for dapagliflozin 10 mg
- subclinical diastolic dysfunction assessed by supine bicycle diastolic stress echocardiography [ Time Frame: 24-week ]
- the impact of dapagliflozin on patients' functional capacity [ Time Frame: 24-week ]functional capacity measured by maximum oxygen uptake (VO2max), Exercise time, Maximum exercise capacity (METs)
- the impact of dapagliflozin on resting diastolic function [ Time Frame: 24-week ]Diastolic function measured by LV mass index, Grade of diastolic function, Ea velocity, Left atrial volume index
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02751398
|Korea, Republic of|
|Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine|
|Seoul, Korea, Republic of, 120-752|